Yongrenxin Medical Instrument, known as the maker of the implantable artificial heart Evaheart, has raised $100 million in a Series A round led by vaccines maker Sinovac Biotech.
The round, joined by the private equity investment arm of China Taiping Insurance Holdings, the longest-running insurance brand in the country, as well as existing shareholder Vivo Capital, will help the firm to build a healthcare platform for heart failure and severe heart diseases, the firm said in a release on Thursday.
